Manufacturer Laboratory: Gamaleya Center for Epidemiology and Microbiology in Russia.
Type: Vectors (two) * To learn more about the type of vaccines, see our blog “The war has begun. Vaccines against COVID-19 ”.
Dosage: 2 doses with a difference in application time of 21 days.
Ingredients: Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene in the amount of (1.0 ± 0.5) х 1011 particles per dose. Excipients: Tris (hydroxymethyl) aminomethane, sodium chloride, sucrose, magnesium chloride hexahydrate, ethylenediaminetetraacetic acid (EDTA) disodium salt dihydrate, polysorbate-80, ethanol 95%, and water for injection. Component II contains: Active substance: recombinant adenovirus serotype 5 particles containing SARS-CoV-2 protein S gene in the amount of (1.0 ± 0.5) х 1011 particles per dose. Excipients: Tris (hydroxymethyl) aminomethane, sodium chloride, sucrose, magnesium chloride hexahydrate, EDTA disodium salt dihydrate, polysorbate-80, ethanol 95%, and water for injection.
Injection site: Intramuscular in the arm.
Recommended age: 18 years old and up.
It is not recommended to apply if: You have had severe allergic reactions to ingredients in the vaccine.
Immediate Allergic Reactions:
EXPECTED SYMPTOMS
In the injection arm:
Pain
Swelling
Sensitivity
In the body in general:
Fever up to 38.5°C (101.3°F)
Cough
General weakness or fatigue
Throat pain
Headache
Special considerations: Check with your doctor before applying the vaccine if you meet any of the following points:
You have allergies, specify which ones.
Have fever.
You have a blood disorder (such as Hemophilia) or if you are taking anticoagulants.
You have a condition that compromises your immune system (eg Lupus) or you take medications that affect your immune system.
You are pregnant or plan to become pregnant.
You are breastfeeding.
You were inoculated with another COVID-19 vaccine.
Safety
This vaccine is approved for use by the Ministry of Health of Russia, as well as the approval of Emergency use of the Institutes of Health of Belarus, Argentina, Hungary, United Arab Emirates, Algeria, Bolivia, Serbia, Iran and Mexico.
An Independent Data Monitoring Committee confirmed that no serious adverse effects related to the vaccine were observed, nor were there cases of severe allergy or anaphylactic shock.
Effectiveness: In clinical trials, it registered an effectiveness of 91.6% for the prevention of COVID-19 cases, laboratory data with people without evidence of previous infections.
Thanks to your preference, we are experiencing a high volume of phone calls in all of our hospitals. If you cannot communicate by phone, please contact us through a form request
